A new study suggests that applying a deep learning algorithm to routine abdominal CT scans could help identify fall risk ...

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the ...

Shares of Corvus Pharmaceuticals rose after its investigational drug soquelitinib showed positive results in an early-stage trial in atopic dermatitis patients. The stock surged 50% to $12.10 in ...

Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug therapy, nipocalimab, met its primary endpoint and multiple key secondary ...

BOULDER, Colo., Jan. 8, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of ...

Ultragenyx Pharmaceutical has reported the failure of a pair of late-phase brittle bone disease trials, prompting the biotech to prepare to significantly reduce its spending. The studies tested the ...

Immutep ( (IMMP)) has issued an announcement. On 22 December 2025, Immutep reported positive initial results from a placebo-controlled, double-blind first-in-human Phase I trial of IMP761, its ...

Anixa Biosciences ( (ANIX)) just unveiled an announcement. On December 11, 2025, Anixa Biosciences announced positive final data from its Phase 1 clinical trial of an investigational breast cancer ...

Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared to baseline, with a 9.4% reduction in visceral fat (p=0.02), a 4.5% ...

SYNC-T demonstrated high efficacy in resolving bone metastases in metastatic prostate cancer, achieving an 87% overall response rate in a phase 1 trial. The therapy involves a minimally-invasive ...

(UroToday.com) The 2025 SUO annual meeting featured a prostate cancer session and a late breaking abstract presentation by Dr. Scott Tagawa discussing top line results from PSMAddition, a Phase 3 ...

Results from the BRUIN CLL-314 study comparing Jaypirca (pirtobrutinib) to Imbruvica (ibrutinib) – the first-ever head-to-head Phase 3 study versus a covalent BTK inhibitor to include treatment-naïve ...